vTv Therapeutics (VTVT) Expected to Release Quarterly Earnings on Thursday

Key Points

• vTv Therapeutics is expected to report Q3 2026 results before the market opens on November 5. Analysts forecast a loss of $1.07 per share and revenue of approximately $0.33 million; the company previously reported a larger-than-expected Q2 loss of $1.05 per share.
• VTVT shares opened at $25.72, versus a 52-week range of $19.80 to $44.00, with a market capitalization of roughly $101 million. The stock trades below its 50-day and 200-day moving averages.
• Analyst sentiment remains generally positive despite mixed ratings, with a consensus “Moderate Buy” rating and an average price target of $55.83. vTv is a clinical-stage biotech developing oral treatments for metabolic and neurological diseases, including its lead type 1 diabetes candidate TTP399.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.07) per share and revenue of $0.33 million for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.08). On average, analysts expect vTv Therapeutics to post ($2.35) EPS for the current fiscal year and ($4.53) EPS for the next fiscal year.

vTv Therapeutics Price Performance

VTVT stock opened at $25.72 on Thursday. vTv Therapeutics has a 52 week low of $19.80 and a 52 week high of $44.00. The firm has a 50 day moving average of $30.57 and a 200 day moving average of $33.66. The stock has a market capitalization of $101.34 million, a PE ratio of -24.26 and a beta of 0.21.

Analyst Upgrades and Downgrades

VTVT has been the subject of a number of research reports. Wall Street Zen cut vTv Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, October 24th. Lifesci Capital upgraded vTv Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 2nd. Weiss Ratings cut shares of vTv Therapeutics from a "sell (d+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. HC Wainwright reduced their target price on vTv Therapeutics from $45.00 to $42.00 and set a "buy" rating for the company in a report on Thursday, August 6th. Finally, BTIG Research reissued a "buy" rating and issued a $57.00 price target on shares of vTv Therapeutics in a research note on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $55.83.

About vTv Therapeutics

vTv Therapeutics Inc NASDAQ: VTVT is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.